IL292391A - Bracelets and methods for treating acromegaly - Google Patents
Bracelets and methods for treating acromegalyInfo
- Publication number
- IL292391A IL292391A IL292391A IL29239122A IL292391A IL 292391 A IL292391 A IL 292391A IL 292391 A IL292391 A IL 292391A IL 29239122 A IL29239122 A IL 29239122A IL 292391 A IL292391 A IL 292391A
- Authority
- IL
- Israel
- Prior art keywords
- sirna
- certain embodiments
- group
- alkyl
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962925659P | 2019-10-24 | 2019-10-24 | |
| PCT/US2020/057185 WO2021081420A2 (en) | 2019-10-24 | 2020-10-23 | Conjugates and methods for treating acromegaly |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL292391A true IL292391A (en) | 2022-06-01 |
Family
ID=75620892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL292391A IL292391A (en) | 2019-10-24 | 2020-10-23 | Bracelets and methods for treating acromegaly |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220288214A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4048801A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7668032B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN114616339A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2020371736A1 (cg-RX-API-DMAC10.html) |
| BR (1) | BR112022007725A2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3158917A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL292391A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021081420A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI859114B (zh) * | 2016-04-11 | 2024-10-21 | 加拿大商艾爾布圖斯生技公司 | 靶向組合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2322665A1 (en) * | 2004-05-14 | 2011-05-18 | Rosetta Genomics Ltd | MicroRNAs and uses thereof |
| JP6487913B2 (ja) * | 2013-07-02 | 2019-03-20 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | 成長ホルモン受容体のモジュレータ |
| WO2015168618A2 (en) * | 2014-05-01 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating growth hormone receptor expression |
| US10570169B2 (en) | 2014-05-22 | 2020-02-25 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| EP3151839A4 (en) * | 2014-06-06 | 2018-02-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds |
| EP3228326A1 (en) | 2016-04-05 | 2017-10-11 | Silence Therapeutics GmbH | Nucleic acid linked to a trivalent glycoconjugate |
| US11015198B2 (en) | 2017-04-05 | 2021-05-25 | Silence Therapeutics Gmbh | Products and compositions |
| WO2018185253A1 (en) * | 2017-04-05 | 2018-10-11 | Silence Therapeutics Gmbh | Ligand modified double-stranded nucleic acids |
| WO2018237245A1 (en) * | 2017-06-23 | 2018-12-27 | University Of Massachusetts | TWO TAIL SELF-ADMINISTRATION SIRNA AND ASSOCIATED METHODS |
| US20210155926A1 (en) * | 2018-04-05 | 2021-05-27 | Silence Therapeutics Gmbh | siRNAs WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDS |
-
2020
- 2020-10-23 CN CN202080075748.1A patent/CN114616339A/zh active Pending
- 2020-10-23 JP JP2022523585A patent/JP7668032B2/ja active Active
- 2020-10-23 EP EP20879819.9A patent/EP4048801A4/en not_active Withdrawn
- 2020-10-23 IL IL292391A patent/IL292391A/en unknown
- 2020-10-23 BR BR112022007725A patent/BR112022007725A2/pt unknown
- 2020-10-23 WO PCT/US2020/057185 patent/WO2021081420A2/en not_active Ceased
- 2020-10-23 AU AU2020371736A patent/AU2020371736A1/en not_active Abandoned
- 2020-10-23 US US17/770,504 patent/US20220288214A1/en not_active Abandoned
- 2020-10-23 CA CA3158917A patent/CA3158917A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4048801A4 (en) | 2023-11-22 |
| JP7668032B2 (ja) | 2025-04-24 |
| WO2021081420A3 (en) | 2021-06-03 |
| BR112022007725A2 (pt) | 2022-08-16 |
| AU2020371736A1 (en) | 2022-06-02 |
| EP4048801A2 (en) | 2022-08-31 |
| WO2021081420A2 (en) | 2021-04-29 |
| CA3158917A1 (en) | 2021-04-29 |
| CN114616339A (zh) | 2022-06-10 |
| US20220288214A1 (en) | 2022-09-15 |
| JP2022553056A (ja) | 2022-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12043833B2 (en) | Targeted compositions | |
| CN115175894B (zh) | 纳米材料 | |
| CA3118142A1 (en) | Therapeutic methods | |
| US20220387600A1 (en) | Conjugates and methods for treating liver fibrosis | |
| JP7190794B2 (ja) | 核酸医薬及び多分岐脂質の複合体 | |
| US20250270555A1 (en) | Organic compositions to treat beta-catenin-related diseases | |
| CN106459969B (zh) | 用于调节生长激素受体表达的组合物和方法 | |
| CN120884604A (zh) | 寡核苷酸组合物及其使用方法 | |
| JP2022534069A (ja) | 核酸、薬物組成物及び複合体並びに調製方法と使用 | |
| CA3120580A1 (en) | Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use | |
| US20240052349A1 (en) | Targeted conjugates comprising modified sirna | |
| JP7668032B2 (ja) | 先端巨大症を処置するためのコンジュゲート及び方法 | |
| JP6774965B2 (ja) | カチオン性脂質としての化合物 | |
| NZ787057A (en) | Targeted nucleic acid conjugate compositions | |
| CN119662638A (zh) | 一种调节血管紧张素原agt表达的双链rna组合物及其应用 | |
| HK40057109A (en) | Targeted compositions |